Bone marrow-derived aldehyde dehydrogenase-bright stem and progenitor cells for ischemic repair

Congestive Heart Failure

Volumn 15, Issue 4, 2009, Pages 202-206

  Keller, Laurence H ^a,b  

^a Aldagen Inc   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED LEUKOCYTE CELL ADHESION MOLECULE; ALDEHYDE DEHYDROGENASE; CD133 ANTIGEN; CD34 ANTIGEN; CD38 ANTIGEN; ENDOGLIN; INTERLEUKIN 7 RECEPTOR; STEM CELL FACTOR RECEPTOR;

ANGIOGENESIS; ARTICLE; CELL LINEAGE; CELL POPULATION; CELL TYPE; CLINICAL TRIAL; EXPERIMENTAL MODEL; FOLLOW UP; HEART FAILURE; HEMATOPOIETIC STEM CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HINDLIMB; HUMAN; ISCHEMIC HEART DISEASE; LIMB BLOOD FLOW; LIMB ISCHEMIA; MEDICAL RESEARCH; MESENCHYMAL STEM CELL; METHODOLOGY; NEURAL STEM CELL; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE REPAIR; TREATMENT OUTCOME;

ALDEHYDE DEHYDROGENASE; ANIMALS; BONE MARROW CELLS; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; ELECTROPHYSIOLOGIC TECHNIQUES, CARDIAC; HUMANS; ISCHEMIA; STEM CELLS;

EID: 67651230323     PISSN: 15275299     EISSN: 17517133     Source Type: Journal    
DOI: 10.1111/j.1751-7133.2009.00101.x     Document Type: Article

References (36)

1. Burt RK, Loh Y, Pearce W, et al. Clinical applications of blood-derived and marrow-derived stem cells for nonmalignant diseases. JAMA. 2008;299:925-936.
2. Abdel-Latif A, Bolli R, Tleyjeh IM, et al. Adult bone marrow-derived cells for cardiac repair: A systematic review and analysis. Arch Intern Med. 2007;167:989-997.
3. Lipinski MJ, Biondi-Zoccai GGL, Abbate A, et al. Impact of intracoronary cell therapy on left ventricular function in the setting of acute myocardial infarction: A collaborative systematic review and meta-analysis of controlled clinical trials. J Am Coll Cardiol. 2007;50:1761-1767.
4. Martin-Rendon E, Brunskill SJ, Hyde CJ, et al. Autologous bone marrow stem cells to treat acute myocardial infarction: A systematic review. Eur Heart J. 2008;29:1807-1818.
5. Cai J, Weiss ML, Rao MS. In search of "stemness". Exp Hematol. 2004;32:585-598.
6. Blomhoff R, Blomhoff HK. Overview of retinoid metabolism and function. J Neurobiol. 2006;66:606-630.
7. Chute JP, Muramoto GG, Whitesides J, et al. Inhibition of aldehyde dehydrogenase and retinoid signaling induces the expansion of human hematopoietic stem stells. Proc Natl Acad Sci USA. 2006;103:103.
8. Sladek NE. Human aldehyde dehydrogenases: Potential pathological, pharmacological, and toxicological impact. J Biochem Mol Toxicol. 2003;17:7-23.
9. Vasiliou V, Pappa A, Petersen DR. Role of aldehyde dehydrogenases in endogenous and xenobiotic metabolism. Chem Biol Interact. 2000;129:1-19.
10. Mehta K. Retinoids as regulators of gene transcription. J Biol Regul Homeost Agents. 2003;17:1-12.
11. Storms RW, Trujillo AP, Springer JB, et.al. Isolation of primitive human hematopoietic progenitors on the basis of aldehyde dehydrogenase activity. Proc Natl Acad Sci USA. 1999;96:9118-9123.
12. Kastan MB, Schlaffer E, Russo JE, et al. Direct demonstration of elevated aldehyde dehydrogenase in human hematopoietic progenitor cells. Blood. 1990;75:1947-1950.
13. Jones R J, Barber JP, Vala MS, et al. Assessment of aldehyde dehydrogenase in viable cells. Blood. 1995;85:2742-2746.
14. Fallon P, Gentry T, Balber AE, et al. Mobilized peripheral blood SSCloALDHbr cells have the phenotypic and functional properties of primitive haematopoietic cells and their number correlates with engraftment following autologous transplantation. Br J Haematol. 2003;122:99-108.
15. Storms RW, Green PD, Safford KM, et al. Distinct hematopoietic progenitor compartments are delineated by the expression of aldehyde dehydrogenase and CD34. Blood. 2005;106:95-102.
16. Hess DA, Meyerrose TE, Wirthlin L, et al. Functional characterization of highly purified human hematopoietic repopulating cells isolated according to aldehyde dehydrogenase activity. Blood. 2004;104:1648-1655.
17. Hess DA, Wirthlin L, Craft TP, et al. Selection based on CD133 and high aldehyde dehydrogenase activity isolates long-term reconstituting human hematopoietic stem cells. Blood. 2006;107:2162-2169.
18. Gentry T, Foster S, Winstead L, et al. Simultaneous isolation of human BM hematopoietic, endothelial and mesenchymal progenitor cells by flow sorting based on aldehyde dehydrogenase activity: Implications for cell therapy. Cytotherapy. 2007;93:259-274.
19. Capoccia BJ, Robson DL, Levac KD, et al. Revascularization of ischemic limbs after transplantation of human bone marrow cells with high aldehyde dehydrogenase activity. Blood. 2009;113:5340-5351.
20. Lloyd-Jones D, Adams R, Carnethon M, et.al. Heart disease and stroke statistics - 2009 update: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2009;119:e21-e181.
21. Booz GW. G-CSF-based stem cell therapy for the heart - unresolved issues part A: Paracrine actions, mobilization, and delivery. Congest Heart Fail. 2007;13:221-227.
22. Perin EC, Dohmann HFR, Borojevic R, et al. Improved exercise capacity and ischemia 6 and 12months after transendocardial injection of autologous bone marrow mononuclear cells for ischemic cardiomyopathy. Circulation. 2004;110(suppl II):II-213-II-218.
23. Wollert KC, Drexler H. Clinical applications of stem cells for the heart. Circ Res. 2005;96:151-163.
24. Perin EC, Dohman HFR, Borojevic R, et al. Transendocardial, autologous bone marrow cell transplantation for severe, chronic ischemic heart failure. Circulation. 2003;107:2294-2302.
25. Gao LR, Wang ZG, Zhu ZM, et al. Effect of intracoronary transplantation of autologous bone marrow-derived mononuclear cells on outcomes of patients with refractory chronic heart failure secondary to ischemic cardiomyopathy. Am J Cardiol. 2006;98:597-602.
26. The SAGE Group reports that in 2006 approximately 2 million people in the United States suffered from critical limb ischemia. The SAGE Group website. http://thesagegroup.us/press%20releases/april17_2007.html. Accessed May 7, 2009.
27. Rutherford RB, Baker JD, Ernst C, et al. Recommended standards for reports dealing with lower extremity ischemia: Revised version. J Vasc Surg. 1997;26:517-538.
28. Nehler MR, McDermott MM, Treat-Jacobson D, et.al. Functional outcomes and quality of life in peripheral arterial disease: Current status. Vasc Med. 2003;8:115-126.
29. Second European Consensus Document on chronic critical leg ischemia. Circulation. 1991;84(suppl 4):IV1-IV26.
30. Bailey CM, Saha S, Magee TR, et al. A 1year prospective study of management and outcome of subjects presenting with critical lower limb ischaemia. Eur J Vasc Endovasc Surg. 2003;25:131-134.
31. Dormandy J, Heeck L, Vig S. The fate of patients with critical leg ischemia. Semin Vasc Surg. 1999;12:142-147.
32. Norgren L, Hiatt WR, Dormandy JA, et.al. Inter-Society Consensus for the management of peripheral artery disease (TASC II). J Vasc Surg. 2007;45(suppl):S5-S67.
33. Second European Consensus Document on chronic critical leg ischemia. Eur J Vasc Surg. 1992;6(suppl):A1-A32.
34. Tatesishi-Yugama E, Matsubara H, Murohara T, et al. Therapeutic angiogenesis for patients with limb ischemia by autologous transplantation of bone marrow cells: A pilot study and a randomised controlled trial. Lancet. 2002;360:427-435.
35. Cobellis G, Silvestroni A, Lillo S, et al. Long-term effects of repeated autologous transplantation of bone marrow cells in patients affected by peripheral arterial disease. Bone Marrow Transplant. 2008;42:667-672.
36. Chochola M, Pytlik R, Kobylka P, et al. Autologous intra-arterial infusion of bone marrow mononuclear cells in patients with critical leg ischemia. Int Angiol. 2008;27:281-290.